Skip to main content
OpenTrials
Completed

NCT Number: NCT01960322

Improving Medication-taking After Liver Transplant

The specific aim is to pilot-test our developed intervention manual's ability to improve patients' adherence to medications and medical outcomes (rejection rate, liver enzyme levels) in participating centers.

Completed

Looking for future studies?

Notify Me

Key information

Age range

11 year–19 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

UCLA Mattell Children's Hospital, Los Angeles, California, United States

Loading trial locations.

About this study

Nonadherence (not taking the medications as prescribed) is the most common cause of late acute rejection in children who have had a liver transplant, and thus is associated with graft loss, increased expenditures on care, and ultimately death. Researchers in this application developed a biomarker to identify nonadherence, calculating the standard deviation (SD) of consecutive immunosuppressant blood levels for each patient to capture the degree of variability between individual levels (higher SD = less consistent levels). By applying a threshold, this marker identifies nonadherent patients. A consortium of transplant centers is currently testing this marker through the MALT (Medication Adherence in children who had a Liver Transplant) study. MALT investigators now propose to take advantage of this existing collaboration to pilot-test an intervention to improve adherence in patients who are identified by this marker.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The patient is between 11-19 years of age at enrollment.
  • Guardian's consent, child assent (in accordance with each institution's IRB policies).
  • The patient is prescribed tacrolimus (either brand or generic formulation).
  • The patient has been seen in the enrolling center's clinic at least once in the last two years.
  • The patient's SD of tacrolimus was > 2.0 in the year prior to enrollment, with at least 3 levels present to make this determination.
  • The patient and at least one guardian speaks English or Spanish at a level that allows her / him to understand the study procedures and consent to the study.

Exclusion criteria

  • The patient received a liver transplant less than 1 year prior to enrollment.
  • The patient has had more than one transplant (including marrow replacement).
  • The patient has had biopsy-proven rejection within the past six months.
  • The patient has been diagnosed with Hepatitis C.
  • The treating physician has instructed the patient not to obtain tacrolimus levels for at least one year in the past year.
  • The guardian or child (in a developmentally-appropriate manner) do not understand the study procedures. This will be verified by asking both guardian and child to repeat the study procedures.
  • The patient is only seen for consultation - most or all of the child's routine care is provided at another center (or in a community clinic).
  • Either the patient or the guardian is actively psychotic or severely disoriented due to any cause, including hepatic encephalopathy (temporary exclusion) or severely mentally retarded as defined in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV).
  • The patient is not medically stable or is hospitalized.

Treatment and study plan

Telemetric

Behavioral

A manualized behavioral management approach focusing on avoidance and addressing barriers to adherence, delivered via telephone or internet chat applications.

Primary outcomes

  1. Change in Adherence

    Time frame: at baseline and one year

    Change in Adherence at one year compared to at baseline measured via the Standard Deviation of Tacrolimus levels obtained

Secondary outcomes

  1. Change in Incidence of rejection

    Time frame: at baseline and at one year

    Change in Incidence of rejection compared at one year to baseline

  2. Liver Enzyme Levels

    Time frame: at baseline

  3. Liver Enzyme Levels

    Time frame: at one year

  4. Feasibility

    Time frame: at one year

    Participation in the intervention (receive all of the remote interactions called for in the manual, presented as a percentage of received / offered during the intervention active phase, 1 year)

Sponsors and collaborators

Lead sponsor

Icahn School of Medicine at Mount Sinai

Other

Collaborators

  • Children's Hospital Medical Center, Cincinnati
  • The Emmes Company, LLC
  • University of California, Los Angeles
  • University of Pittsburgh

Registry information

Official study title

Intervention After MALT (I-AM): Feasibility of Improving Adherence Among Pediatric and Adult Cardiac Transplant Patients Using a Telemetric Intervention

Acronym: I-AM

Important dates

Study start
2014
Primary completion
2016
Study completion
2016
First posted
Oct 10, 2013
Registry last updated
Jul 1, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.